TNF-alpha Blocker Therapy and Solid Malignancy Risk in ANCA-Associated Vasculitis

Simple item page
dc.contributor.authorSilva, Francisco
dc.contributor.authorCisternas, Marcela
dc.contributor.authorSpecks, Ulrich
dc.date.accessioned2024-01-10T13:43:58Z
dc.date.available2024-01-10T13:43:58Z
dc.date.issued2012
dc.description.abstractANCA-associated vasculitides (AAV) are small vessel systemic vasculitis syndromes associated with the potential for high morbidity and mortality. This group includes granulomatosis with polyangiitis (Wegener's, GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (Churg-Strauss, EGPA). The standard treatment consists of a combination of glucocorticoids and potent immunosuppressant drugs. These have broad mechanisms of action as well as important adverse effects. Efforts have been made to investigate novel agents with better-defined and narrower mechanisms of action, such as biologics, including TNF-alpha blockers. Etanercept, a well-known TNF-alpha blocker evaluated for GPA in the Wegener's Granulomatosis Etanercept Trial (WGET), was associated with an increase in the development of solid malignancies in comparison to placebo during that trial period. A 5-year follow-up after the WGET trial showed a sustained increase in incidence of solid malignancies, but this could no longer be solely attributed to etanercept exposure. These studies raised concerns about the use of the family of TNF-alpha blockers in AAV. Here, we review the evidence about the association between therapeutic inhibition of tumor necrosis factor (TNF-alpha) by etanercept and other TNF-alpha blockers with the development of solid malignancies in GPA and other AAV.
dc.description.funderGenentech
dc.fechaingreso.objetodigital2024-03-14
dc.format.extent8 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1007/s11926-012-0290-2
dc.identifier.issn1523-3774
dc.identifier.pubmedidMEDLINE:22956157
dc.identifier.urihttps://doi.org/10.1007/s11926-012-0290-2
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/78806
dc.identifier.wosidWOS:000324992500003
dc.information.autorucMedicina;Cisternas M;S/I;4233
dc.information.autorucMedicina;Silva F;S/I;7423
dc.issue.numero6
dc.language.isoen
dc.nota.accesoContenido parcial
dc.pagina.final508
dc.pagina.inicio501
dc.publisherSPRINGER
dc.revistaCURRENT RHEUMATOLOGY REPORTS
dc.rightsacceso restringido
dc.subjectVasculitis
dc.subjectANCA-associated vasculitis
dc.subjectBiologicals
dc.subjectTNF-alpha blockers
dc.subjectEtanercept
dc.subjectInfliximab
dc.subjectAdalimumab
dc.subjectMalignancy
dc.subjectSolid malignancy
dc.subjectRisk
dc.subjectCancer
dc.subjectTreatment
dc.subjectTherapy
dc.subjectTUMOR-NECROSIS-FACTOR
dc.subjectREFRACTORY WEGENERS-GRANULOMATOSIS
dc.subjectPOPULATION-BASED COHORT
dc.subjectRANDOMIZED CONTROLLED-TRIALS
dc.subjectSQUAMOUS-CELL CARCINOMA
dc.subjectOPEN-LABEL TRIAL
dc.subjectRHEUMATOID-ARTHRITIS
dc.subjectLONG-TERM
dc.subjectNECROTIZING SCLERITIS
dc.subjectSYSTEMIC VASCULITIS
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleTNF-alpha Blocker Therapy and Solid Malignancy Risk in ANCA-Associated Vasculitis
dc.typeartículo
dc.volumen14
sipa.codpersvinculados4233
sipa.codpersvinculados7423
sipa.indexScopus
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2024-03-14. TNF-α Blocker Therapy and Solid Malignancy Risk in ANCA-Associated Vasculitis.pdf
Size:
121.19 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas